Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma

British Journal of Haematology

Volumn 158, Issue 6, 2012, Pages 805-809

  Martino, Alessandro ^a   Campa, Daniele ^a   Jamroziak, Krzysztof ^b   Reis, Rui Manuel ^c,d   Sainz, Juan ^e,f   Buda, Gabriele ^g   García Sanz, Ramón ^h   Lesueur, Fabienne ⁱ   Marques, Herlander ^c   Moreno, Victor ^j   Jurado, Manuel ^e,f   Ríos, Rafael ^e,f   Szemraj Rogucka, Zofia ^b   Szemraj, Janusz ^b   Tjønneland, Anne ^k   Overvad, Kim ^l   Vangsted, Annette Juul ^m   Vogel, Ulla ⁿ   Mikala, Gabor ^o   Kádár, Katalin ^p   Szombath, Gergely ^q   Varkonyi, Judit ^q   Orciuolo, Enrico ^g   Dumontet, Charles ^r   Gemignani, Federica ^g   Rossi, Anna Maria ^g   Landi, Stefano ^g   Petrini, Mario ^g   Houlston, Richard S ^s   Hemminki, Kari ^a,t   Canzian, Federico ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF MINHO   (Portugal)

^d BARRETOS CANCER HOSPITAL   (Brazil)

^e UNIVERSITY OF GRANADA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g UNIVERSITY OF PISA   (Italy)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^j UNIVERSITY OF BARCELONA   (Spain)

^k INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^l AARHUS UNIVERSITY   (Denmark)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^o Szent Laszlo Hospital   (Hungary)

^p SEMMELWEIS UNIVERSITY   (Hungary)

^q SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^r UNIVERSITÉ LYON 1   (France)

^s INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^t LUND UNIVERSITY   (Sweden)

more..

Author keywords

Association study; Genetic susceptibilty; Multiple myeloma; Single nucleotide polymorphism

Indexed keywords

DYNEIN ADENOSINE TRIPHOSPHATASE; MYC PROTEIN;

CANCER RISK; CARCINOGENESIS; CDCA7L GENE; CHROMOSOME 2P; CHROMOSOME 3P; CHROMOSOME 7P; CONTROLLED STUDY; DNAH11 GENE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

BIOLOGICAL SPECIMEN BANKS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENES, MYC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GERMANY; GREAT BRITAIN; HUMANS; MALE; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84865544766     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09244.x     Document Type: Letter

References (9)

1. Altieri, A., Chen, B., Bermejo, J.L., Castro, F. & Hemminki, K. (2006) Familial risks and temporal incidence trends of multiple myeloma. European Journal of Cancer, 42, 1661-1670.
2. Broderick, P., Chubb, D., Johnson, D.C., Weinhold, N., Forsti, A., Lloyd, A., Olver, B., Ma, Y.P., Dobbins, S.E., Walker, B.A., Davies, F.E., Gregory, W.A., Child, J.A., Ross, F.M., Jackson, G.H., Neben, K., Jauch, A., Hoffmann, P., Muhleisen, T.W., Nothen, M.M., Moebus, S., Tomlinson, I.P., Goldschmidt, H., Hemminki, K., Morgan, G.J. & Houlston, R.S. (2011) Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nature Genetics, 44, 58-61.
3. Campa, D., Martino, A., Sainz, J., Buda, G., Jamroziak, K., Weinhold, N., Reis, R.M., García-Sanz, R., Jurado, M., Ríos, R., Szemraj-Rogucka, Z., Marques, H., Lesueur, F., Bugert, P., Moreno, V., Szemraj, J., Orciuolo, E., Gemignani, F., Rossi, A.M., Dumontet, C., Petrini, M., Goldschmidt, H., Landi, S. & Canzian, F. (2012) Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. British Journal of Haematology, 157, 331-338.
4. Chng, W.J., Huang, G.F., Chung, T.H., Ng, S.B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P.L. & Fonseca, R. (2011) Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia, 25, 1026-1035.
5. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., Chesi, M., Schinzel, A.C., McKeown, M.R., Heffernan, T.P., Vakoc, C.R., Bergsagel, P.L., Ghobrial, I.M., Richardson, P.G., Young, R.A., Hahn, W.C., Anderson, K.C., Kung, A.L., Bradner, J.E. & Mitsiades, C.S. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 146, 904-917.
6. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. & Parkin, D.M. (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France.
7. International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
8. Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G. & Anderson, K.C. (2009) Multiple myeloma. Lancet, 374, 324-339.
9. Richardson, P.G., Laubach, J., Mitsiades, C.S., Schlossman, R., Hideshima, T., Redman, K., Chauhan, D., Ghobrial, I.M., Munshi, N. & Anderson, K.C. (2011) Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. British Journal of Haematology, 154, 755-762.